Text size Jeenah Moon / Getty Images Pfizer hopes to get emergency food authorization from the Food and Drug Administration for its Covid-19 vaccine, produced in collaboration with BioNTech, in October – a timeline that is possible, and not the only positive for the biotech industry, according to a Mizuho …
Read More »Novartis gets green light to challenge Roche, Sanofi with delayed MS with Kesimpta
Back in June, the FDA extended its deadline for decision for Novartis’ multiple sclerosis prospect ofatumumab by three months. But it turns out that the agency was not needed for so long. U.S. regulators on Thursday removed the drug, which will go by the name Kesimpta, into relapsing forms of …
Read More »Johnson & Johnson adds debt frenzy, borrowing $ 7.5 billion to buy Momenta
The Johnson & Johnson logo is displayed outside the company’s headquarters in New Brunswick, NJ Bloomberg News Johnson & Johnson on Thursday announced their top AAA credit ratings to borrow $ 7.5 billion in cheap financing for their acquisition of Momenta Pharmaceuticals, Inc. J&J, which makes drugs, consumables and medical …
Read More »A tidal wave of news about covid vaccine is on the market
Text size Data from BioNTech and Pfizer were particularly promising. Jeenah Moon / Getty Images After a hiatus from a late summer break, the news of a Covid-19 vaccine is heating up again as a handful of leading programs are rapidly moving to a decisive phase. Reports from several companies …
Read More »CureVac and EU in advanced talks for 225 million doses of Covid-19 vaccine
Shares of CureVac NV rose Thursday after the German biotech company said it was in advanced talks to deliver at least 225 million doses of a potential Covid-19 vaccine to EU member states. CureVac said talks with the EC, the executive arm of the European Union, include an option to …
Read More »